Get all premium features to the best stock analysis tool

Although the revenue and EPS for Journey Medical (DERM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™  during FY2025 Payer access for Emrosi™  available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.

Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET

Journey Medical offers a rare microcap biopharma setup with a stable, cash-generating dermatology portfolio and a high-upside new drug, Emrosi. DERM's commercial infrastructure enables rapid Emrosi adoption, with Q3 net sales of $4.9M and over 2,700 unique prescribers post-launch. Emrosi outperformed Oracea in Phase 3 trials, and current valuation assigns minimal credit to its growth potential despite management's $200M peak sales target.

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of low-dose oral minocycline (“DFD-29” or commercially known as “Emrosi™) on skin, gastrointestinal (“GI”) and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology.

Journey Medical Corporation ( DERM ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO & Director Joseph Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Scott Henry - Alliance Global Partners, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mayank Mamtani - B.